BioMed X Launches Ukraine Funding Programme
BioMed X (Heidelberg, Germany) has announced the start of its “Ukraine Refugee Funding Programme” that supports doctoral students and masters-level researchers in the life sciences who cannot continue their work at institutions in Ukraine. In collaboration with some of its partners, BioMed X aims to give these scientists the opportunity to continue their work in a research group at the BioMed X Institute in Heidelberg for a period of up to four years. Candidates should have a master’s degree, as well as research experience, in either molecular/cell biology, bio-organic chemistry, pharmacology, or physics. Knowledge of the German language is not required.
Thomas Rückle, Senior VP and Head of Research at the BioMed X Institute, commented: “The situation in Ukraine is a tragedy that requires a joint effort to offer support and help. Our BioMed X Institute is a place where early-career scientists are given the opportunity to develop themselves. Together with some of our partners we launched this funding programme because we sincerely hope to provide a scientific home for some of the researchers who cannot continue their career in Ukraine.”
For further information, please click here: https://bio.mx/landingpage/ukraine
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
